Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

My last U.S.-focused dispatch, The View from D.C. published in December, reported significant tumult across the regulatory apparatus and within the psychedelics advocacy realm. Beneath the noise, however, I observed a quiet confidence that multiple FDA approvals were close at hand. On my most recent trip, earlier this month, I again heard of chaos among federal agencies and infighting between…

Source